My view (opinion only) is that these results are highly unlikely to be negative and that should trigger a re-rating as much on the implications for the CHF trial as for the potential commercialization for LVAD. We are all gambling here but I think the share price still lags real value given the reduction in risk and increase in potential earnings we have seen over the past two months or so.
- Forums
- ASX - By Stock
- MSB
- Ann: End-Stage HF Results Selected For AHA Scientific Sessions
Ann: End-Stage HF Results Selected For AHA Scientific Sessions, page-52
-
-
- There are more pages in this discussion • 36 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.15 |
Change
0.000(0.00%) |
Mkt cap ! $1.295B |
Open | High | Low | Value | Volume |
$1.15 | $1.16 | $1.13 | $1.373M | 1.203M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
20 | 32059 | $1.15 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.15 | 9857 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
19 | 30559 | 1.145 |
20 | 83855 | 1.140 |
16 | 235085 | 1.135 |
8 | 466544 | 1.130 |
5 | 72735 | 1.125 |
Price($) | Vol. | No. |
---|---|---|
1.150 | 11447 | 6 |
1.155 | 74392 | 14 |
1.160 | 116978 | 13 |
1.165 | 60434 | 6 |
1.170 | 106884 | 6 |
Last trade - 12.47pm 22/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |